Chief Executive Officer
Edison Oncology Holding Corp.
Jeffrey Bacha serves as Cheif Executive Officer of Edison Oncology Holding Corp., a company which he founded in 2018 to acquire under-developed cancer therapies fir indications characterized by a significant unmet medical need. Mr. Bacha previously co-Founded DelMar Pharmaceuticals where he served as Chairman and CEO from 2010 thru 2018. Mr. Bacha is a seasoned executive leader with nearly twenty years of life sciences experience in the areas of operations, strategy and finance. His background includes successful public and private company building from both a start-up and turn around perspective; establishing and leading thriving management and technical teams; and raising capital in both the public and private markets. Mr. Bacha serves as a Director of Sernova Corp. (TSX-V: SVA), was the founding CEO of Inimex Pharmaceuticals Inc and co-founder of XBiotech and Urigen Holdings Inc. He has also held positions as and Exec. VP Corporate Affairs & Chief Operating Officer at Clera Inc., VP Corporate Development at Inflazyme Pharmaceuticals Ltd. (TSE: IZP) and Senior Manager & Director at KPMG Health Ventures. Mr. Bacha has been recognized as a “Top 40 under 40” executive by Business in Vancouver magazine and is the former Chair of the Greater Vancouver Economic Council. Mr. Bacha is active in his community as a member of the Board of the Leukemia & Lymphoma Society of Canada and as the former Chairman of the Board for Covenant House Vancouver, an organization dedicated to assisting at-risk and homeless youth to re-enter society. He received his MBA(honors) from the Goizueta Business School at Emory University and a B.Sc. (BioPhysics/Premed) from the University of California, San Diego.